Biomarin Pharmaceutical (BMRN) Non-Current Assets (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Non-Current Assets came in at $4.0 billion in Q1 2026, up 8.34% YoY from $3.7 billion in Q1 2025, and up 9.49% on a QoQ basis from $3.6 billion in Q4 2025.
Biomarin Pharmaceutical (BMRN) Non-Current Assets (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Non-Current Assets data on file, last reported at $4.0 billion in Q1 2026.
- Quarterly Non-Current Assets rose 8.34% year-over-year to $4.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.0 billion (changed 0.0% YoY) and the FY2025 annual result came in at $3.6 billion, down 3.09% from the prior year.
- Non-Current Assets climbed to $4.0 billion in Q1 2026, from $3.6 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $4.0 billion in Q1 2026 to a low of $3.6 billion in Q3 2022.
- A 5-year average of $3.7 billion and a median of $3.7 billion in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2025 — Non-Current Assets slipped 5.36% — and 2026, when it gained 8.34%.
- Tracing BMRN's Non-Current Assets over 5 years: stood at $3.6 billion in 2022, then advanced by 7.23% to $3.9 billion in 2023, then retreated by 3.32% to $3.8 billion in 2024, then dropped by 3.09% to $3.6 billion in 2025, then climbed by 9.49% to $4.0 billion in 2026.
- The last three Non-Current Assets figures came in at $4.0 billion (Q1 2026), $3.6 billion (Q4 2025), and $3.8 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 7.75 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.75 Bn |
| Mar 31, 2026 | 3.99 Bn |
| Dec 31, 2025 | 3.64 Bn |
| Sep 30, 2025 | 3.76 Bn |
| Jun 30, 2025 | 3.65 Bn |
| Mar 31, 2025 | 3.68 Bn |
| Dec 31, 2024 | 3.76 Bn |
| Sep 30, 2024 | 3.79 Bn |
| Jun 30, 2024 | 3.81 Bn |
| Mar 31, 2024 | 3.89 Bn |
| Dec 31, 2023 | 3.89 Bn |
| Sep 30, 2023 | 3.80 Bn |
| Jun 30, 2023 | 3.61 Bn |
| Mar 31, 2023 | 3.59 Bn |
| Dec 31, 2022 | 3.62 Bn |
| Sep 30, 2022 | 3.58 Bn |
| Jun 30, 2022 | 3.63 Bn |
| Mar 31, 2022 | 3.67 Bn |
| Dec 31, 2021 | 3.73 Bn |
| Sep 30, 2021 | 3.67 Bn |